Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 83

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 83
---
 | ​  | ​           |          ​ | ​  | ​             |  107,049,640 | ​ | ​            | 110,960,324 | ​ |
| Accumulated deficit                                                                                                                                                                                                                                                                                                                                                                                                                   | ​ | ​             | -103,934,931 | ​ | ​               |          ​ | ​  | ​           | -5,137,132 | ​  | ​             | -109,072,063 | ​ | ​            | -98,889,581 | ​ |
| Total Stockholders’ Equity                                                                                                                                                                                                                                                                                                                                                                                                            | ​ | ​             |    3,115,711 | ​ | ​               |          — | ​  | ​           | -5,137,132 | ​  | ​             |   -2,021,421 | ​ | ​            |  12,071,041 | ​ |
| ​                                                                                                                                                                                                                                                                                                                                                                                                                                     | ​ | ​             |            ​ | ​ | ​               |          ​ | ​  | ​           |          ​ | ​  | ​             |            ​ | ​ | ​            |           ​ | ​ |
| Total Liabilities and Stockholders’ Equity                                                                                                                                                                                                                                                                                                                                                                                            | ​ | $             |   20,693,630 | ​ | $               |          — | ​  | $           | -7,137,132 | ​  | $             |   13,556,498 | ​ | $            |  33,795,795 | ​ |

| (a) | Reclassification of long-term portion of Vivus Promissory Note to current liability upon Vivus Event of Default. |

| (b) | Represents packaged and bulk Stendra® tablets. |

| (c) | Represents API that the Company has title to based on cumulative Promissory Note payments. |

| (d) | Represents API the Company expected to acquire in the next 12 months. |

| (f) | Represents the collateral value of the inventory and API that was applied against the Promissory Note. |

49

Petros Pharmaceuticals, Inc. Consolidated Statements of Operations (Unaudited)

| Net sales                                    
 Cost of goods sold                           
 Gross profit                                 
 Operating expenses:                          
 Selling, general and administrative          
 Research and development expense             
 Depreciation and amortization expense        
 Intangible asset impairment                  
 Total operating expenses                     
 Loss from operations                         
 Other income (expense):                      
 Gain (Loss) on Vivus Settlement              
 Change in fair value of derivative liability